Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 to 75

Plasma Resuscitation Early for Severe Burn Injury

Official title: Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury (PREEVEnT) Trial

Run by University of Pittsburgh · NCT07212998 · Data updated 2026-11-12

This trial tests whether starting plasma resuscitation right at hospital arrival helps adults with large burns recover better than standard fluids.

More Burn Injury trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment750 (estimated)
SponsorUniversity of Pittsburgh
Academic / other
Locations1 site (Pittsburgh, Pennsylvania)
StatusRecruiting
StartedAugust 31, 2026
Main results expectedAugust 2029
Study endsSeptember 2029
Registry record updatedSeptember 1, 2026
Trial IDNCT07212998 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 to 75 with estimated burn injury of ≥20% total body surface area requiring burn resuscitation and anticipated admission to a burn ICU.

Probably not a fit

Patients with factors indicating very low likelihood of benefit, such as imminent non-survivable injury or exclusion criteria like prolonged CPR or non-survivable status within 24 hours.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, open-label, phase 3 trial enrolling about 750 adults with large 2nd or 3rd degree thermal burns affecting 20% or more of the body. Participants are randomized early in the hospital course to receive plasma resuscitation versus standard care resuscitation. The study aims to see if early plasma can reduce morbidity and mortality from post-injury complications. It uses burn centers within the LITES network over a planned 3-year enrollment period within a 5-year study window. Primary results will inform whether early plasma should become a standard component of burn resuscitation.

Why it matters

Potential benefit: If successful, early plasma resuscitation could reduce complications and improve survival for patients with large thermal burns.

How similar studies have gone: Prior work in resuscitation strategies for burns shows potential benefits in early plasma approaches, but this exact early plasma strategy in large burns is being evaluated for its effectiveness.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Estimated ≥ 20% Total Body Surface Area burn/thermal injury with 2nd or 3rd degree depth
* Anticipated admission to burn ICU

Exclusion Criteria:

* Estimated rBaux score \<55
* Not expected to survive \>24 hours
* Wearing NO PREEVENT opt-out bracelet
* Age \> 75 or \< 18 years of age
* Concomitant traumatic injury with hemorrhagic shock
* Isolated chemical burn/injury
* Isolated deep electrical burn/injury
* Known prisoner
* Known pregnancy
* Cardiac arrest with \> 5 continuous minutes of CPR
* Concern for anoxic injury/ fixed pupils bilaterally
* Objection to study voiced by subject or family member at the scene or at the emergency department/burn center

Where it's running

  • University of Pittsburgh
    Pittsburgh, Pennsylvania, United States
    Recruiting

Study contacts

  • Principal investigator: Jason Sperry, MD — University of Pittsburgh
  • Study coordinator: Jason Sperry, MD
  • Email: sperryjl@upmc.edu
  • Phone: 4128028270

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.